This randomized controlled trial provides robust evidence supporting the therapeutic
efficacy and safety profile of transdermal THC:CBD:CBN formulation in the management of painful diabetic peripheral neuropathy. The demonstrated significant reduction in
multidimensional pain scores, combined with the pharmacokinetic advantages of transdermal delivery and favorable safety outcomes, suggests substantial clinical potential for this therapeutic approach. As the evidence base continues to expand, cannabinoid-based interventions may emerge as a valuable therapeutic option in addressing the complex challenges of neuropathic pain management.
Commentaires